Edward Gould, MD
Nephrology · Nashville, TNNPI 1417191453
Payments from drug & device makers
What this record shows
The money is spread across several categories — consulting fees (37.8%), travel and lodging and food and beverage — rather than concentrated in one kind of arrangement. 3 manufacturers reported payments, led by Pfizer at 59.8% of the total. Reporting peaked in 2019 at $735 and has fallen 97.9% since, to $15 in 2025. That places this record below the midpoint for nephrology clinicians in TN, where the typical reported total is $1,232.
Across 6 payments — averaging $204.76 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Pfizer$735
- C. R. Bard, Inc. & Subsidiaries$465
- Otsuka America Pharmaceutical, Inc.$28
Across 5 payments — averaging $39,087 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Vertex$145K
- Otsuka Pharmaceutical Development & Commercialization, Inc.$39K
- Janssen Research & Development, LLC$12K
What the payments were for
- Consulting fees$46538%
- Travel & lodging$40533%
- Food & beverage$35829%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Pfizer | 3 | $735 |
| C. R. Bard, Inc. & Subsidiaries | 1 | $465 |
| Otsuka America Pharmaceutical, Inc. | 2 | $28 |
How this compares
$1,229 in reported general payments places this provider in the 45th percentile of 229 nephrology providers in Tennessee.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| AuryxiaFerric Citrate | 28 | $43,205 |
| FarxigaDapagliflozin Propanediol | 35 | $40,333 |
| JardianceEmpagliflozin | 11 | $13,419 |
| Sevelamer Carbonate | 27 | $5,322 |
| Clonidine | 11 | $1,643 |
| Nifedipine ErNifedipine | 40 | $1,376 |
| Irbesartan | 65 | $1,279 |
| Potassium Citrate ErPotassium Citrate | 15 | $1,212 |
| Calcium Acetate | 19 | $1,137 |
| Doxazosin Mesylate | 33 | $643 |
| Tamsulosin Hcl | 44 | $567 |
| Carvedilol | 48 | $513 |
| Losartan Potassium | 53 | $456 |
| Allopurinol | 53 | $408 |
| Potassium Chloride | 23 | $398 |
Paid to pharmacies, not to this prescriber.
Other nephrology in Nashville
- Jamie DwyerNashville$461K
- Volker HaaseNashville$123K
- Talat IkizlerNashville$93K
- Julia LewisNashville$87K
- Osama El ShamyNashville$87K
- Thomas GolperNashville$26K
- Anthony LangoneNashville$23K
- James LutherNashville$20K
- Jeffrey HymesNashville$19K
- Roy ZentNashville$17K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.